Characteristics of accelerated disease in chronic myelogenous leukemia.
about
Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment.Subdural hematomas during CML therapy with imatinib mesylate.Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.Utility of a simple prognostic stratification based on platelet counts and serum albumin levels in elderly patients with diffuse large B cell lymphoma.Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemiaGonadotoxic Effects of Nilotinib in Chronic Myeloid Leukemia Treatment Dose in a Mouse ModelTherapeutic choices in younger patients with chronic myelogenous leukemia.The Effect of Imatinib Mesylate for Newly Diagnosed Philadelphia Chromosome-Positive, Chronic-Phase Myeloid Leukemia in Sub-Saharan African Patients: The Experience of Côte d'Ivoire.Chronic myelogenous leukemia: laboratory diagnosis and monitoring.Chronic myelogenous leukemia: treatment and monitoring.Imatinib plus Granulocyte Colony-Stimulating Factor in Chronic Myeloid Leukemia Patients Who Have Achieved Partial or Complete Cytogenetic Response while on Imatinib.Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1).Enumeration and immunohistochemical characterisation of bone marrow basophils in myeloproliferative disorders using the basophil specific monoclonal antibody 2D7.Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experienceCombination of White Blood Cell Count at Presentation With Molecular Response at 3 Months Better Predicts Deep Molecular Responses to Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients.Hypercalcaemia with radiographic abnormalities in chronic myeloid leukaemiaChronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significanceThe long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up.Diagnostic and prognostic value of new biochemical and immunohistochemical parameters in chronic myeloid leukemia.Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.State-of-the-art in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors: evolutionary trends in diagnosis, monitoring and treatment.A nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents.Selection of therapy: rational decisions based on molecular events.The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib.Accelerated Phase CML: Outcomes in Newly Diagnosed vs. Progression From Chronic Phase.Adiponectin enhances Imatinib anti-tumour activity in human chronic myeloid leukaemia cells with serum levels associated with Imatinib efficacy in early chronic phase patients.The Role of Early Molecular Response in the Management of Chronic Phase CML.Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up resultsSurvival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case.Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase.Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors.Correlation between flow cytometric identification of CD33-positive cells and morphological evaluation of myeloblasts in bone marrow of patients with acute myeloblastic leukemia.Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group.Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa.Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse.A study of prognostic factors in blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia.Mixed-lineage eosinophil/basophil crisis in MDS: a rare form of progression.
P2860
Q33357697-560E9905-1C41-44AC-ADA3-63C7024E2D2CQ33362624-2C40ADBB-853B-4360-A6F6-9F5AD498BEFBQ33398183-595DB8B4-EF8A-4B3C-ACF4-D0F8757A9945Q33435420-E100C9CA-3DDB-487A-B91B-C00BEBADA52BQ33632220-E29FD026-765C-4605-B174-5938273822C1Q33716491-FA946DFD-40BB-41A6-954D-533D99A3B447Q34066699-290BD0AE-1A3B-4306-90B3-2906D94B99E1Q34123610-6F8E40EA-5816-4DE9-BAA1-E089BDD4F08CQ34364223-75BBF15B-16AD-479B-9F4A-8F79C409F8DDQ34617628-C4B136A2-8D15-4174-93E5-19D93C248F5AQ34832286-E22450AD-B6A8-411F-9ADD-2E714CCF06D1Q35102183-73ABA71A-D41C-4158-BECE-BC0655EA4698Q35769951-4D2810EC-DCDF-46E4-ABF5-99AEBA0EFBC8Q35849204-92BC0CE6-5F22-4192-90B5-FE5D98B61958Q36478229-AD864C00-EDDE-4E89-89AD-30FFF2330A92Q36612970-1A63006C-A37A-4D1C-91F0-DE2FAB70D4CCQ36788127-D4AAD82F-F7C6-46BB-B8DB-52C3D055A2ADQ37082725-C48073C8-B871-4808-AF85-93808534EFD2Q37132863-43B13A18-97D9-49C9-8AAE-C5D36A5B8D1BQ37163487-EAC4875A-CB58-4CE1-A33E-1C6F16717888Q37461942-43C36431-8702-4CA1-B411-B0E94C35F1EAQ37647076-B5DAD20F-B8C7-4D43-A4B4-1B530C2A27D4Q37657478-D2C46F1A-C36B-4B87-AD18-D263F5AB571EQ37682689-505032D1-480E-46D0-9967-9C9835AA4CFAQ37952910-824910E4-798E-4F6E-BCDB-68F68E2B3E42Q38113416-D1475B45-FAA3-4641-A36C-0B13A5DD79EDQ38757051-99B946D0-BB70-44EF-974B-74E4DD9A29E3Q38856406-946FED3F-F9A2-4DA1-B46A-153E7435F6EDQ39239805-41E1090C-B103-48B4-B262-7E402FCF7F07Q41899882-AA076959-E945-48EA-BDEF-DE24A3F5D0D6Q41948234-874588B8-B5C5-4019-846E-73EA7026E6F8Q43117904-69887EF5-72DF-4441-BE00-1DB75D2BB734Q43621657-0AE629EE-B26D-49B6-85A0-8CD78BE5F38EQ43719917-217FF555-9593-4255-80FF-55FEF553DF5FQ43980276-A7309EDF-A207-46C1-973F-38A8BC1353C7Q44117294-7A85DA47-6DF8-4260-AF15-957B65E481B7Q44529440-4654CB51-04FF-4D4B-8F46-B3E68B8F63EDQ45259654-3C9339BF-F2C9-4033-BEB9-0AFBBBD2ED86Q46084243-858C1B84-11BA-493B-89B5-842A491EB1DDQ46620513-6F2530ED-7E8D-4B2E-A300-28518EEA78E3
P2860
Characteristics of accelerated disease in chronic myelogenous leukemia.
description
1988 nî lūn-bûn
@nan
1988 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
Characteristics of accelerated disease in chronic myelogenous leukemia.
@ast
Characteristics of accelerated disease in chronic myelogenous leukemia.
@en
type
label
Characteristics of accelerated disease in chronic myelogenous leukemia.
@ast
Characteristics of accelerated disease in chronic myelogenous leukemia.
@en
prefLabel
Characteristics of accelerated disease in chronic myelogenous leukemia.
@ast
Characteristics of accelerated disease in chronic myelogenous leukemia.
@en
P2093
P1433
P1476
Characteristics of accelerated disease in chronic myelogenous leukemia.
@en
P2093
Freireich EJ
Kantarjian HM
Keating MJ
McCredie KB
Walters RS
P304
P356
10.1002/1097-0142(19880401)61:7<1441::AID-CNCR2820610727>3.0.CO;2-C
P407
P577
1988-04-01T00:00:00Z